Review

Guillain Barré syndrome

J B Winer

Department of Neurology, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK

Correspondence to:
Dr Winer j.b.winer{at}bham.ac.uk

Guillain Barré syndrome is one of the best examples of a post infectious immune disease and offers insights into the mechanism of tissue damage in other more common autoimmune diseases. Controlled epidemiological studies have linked it to infection with Campylobacter jejuni in addition to other viruses including cytomegalovirus and Epstein Barr virus. The syndrome includes several pathological subtypes, of which the most common is a multifocal demyelinating disorder of the peripheral nerves in close association with macrophages. Evidence from histological examination of peripheral nerve biopsy and postmortem samples suggests that both cell mediated and humoral mechanisms are involved in the pathogenesis. Immunological studies suggest that at least one third of patients have antibodies against nerve gangliosides, which in some cases also react with constituents of the liposaccharide of C jejuni. In the Miller Fisher variant of the disease, these antiganglioside antibodies have been shown to produce neuromuscular block, and may in part explain the clinical signs of that disorder. Treatment with both intravenous immunoglobulin and plasma exchange reduces the time taken for recovery to occur, although mortality remains around 8%, with about 20% of patients remaining disabled.

Key Words: Guillain Barré syndrome • Campylobacter jejuni • antiganglioside antibodies • intravenous immunoglobulin treatment • plasma exchange

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Zhang, Z., Zhang, Z.-Y., Schluesener, H. J. (2009). Compound A, a Plant Origin Ligand of Glucocorticoid Receptors, Increases Regulatory T Cells and M2 Macrophages to Attenuate Experimental Autoimmune Neuritis with Reduced Side Effects. J. Immunol. 183: 3081-3091 [Abstract] [Full Text]  
• Huberle, A., Beyeen, A. D., Ockinger, J., Ayturan, M., Jagodic, M., de Graaf, K. L., Fissolo, N., Marta, M., Olofsson, P., Hultqvist, M., Holmdahl, R., Olsson, T., Weissert, R. (2009). Advanced Intercross Line Mapping Suggests That Ncf1 (Ean6) Regulates Severity in an Animal Model of Guillain-Barre Syndrome. J. Immunol. 182: 4432-4438 [Abstract] [Full Text]  
• Kozminski, M. P. (2008). Miller Fisher Variant of Guillain-Barre Syndrome: A Report of Case. JAOA: Journal of the American Osteopathic Association 108: 51-52 [Full Text]  
• Linenberger, M. L., Price, T. H. (2005). Use of Cellular and Plasma Apheresis in the Critically Ill Patient: Part II: Clinical Indications and Applications. J Intensive Care Med 20: 88-103 [Abstract]  
• Zhang, X., Kiechle, F. L. (2004). Glycosphingolipids in Health and Disease. Annals of Clinical & Laboratory Science 34: 3-13 [Abstract] [Full Text]  
• Bowes, T., Wagner, E. R., Boffey, J., Nicholl, D., Cochrane, L., Benboubetra, M., Conner, J., Furukawa, K., Furukawa, K., Willison, H. J. (2002). Tolerance to Self Gangliosides Is the Major Factor Restricting the Antibody Response to Lipopolysaccharide Core Oligosaccharides in Campylobacter jejuni Strains Associated with Guillain-Barre Syndrome. Infect. Immun. 70: 5008-5018 [Abstract] [Full Text]